PFE
Pfizer Inc. NYSE Closed · opens in 16h 22m
Change in share price, adjusted for splits. Dividends are not included, so a payer's total return is higher than shown.
Related companies
Grouped with PFE by the data provider- MRNAModerna +3.36%
- MRKMerck & Co. +0.18%
- JNJJohnson & Johnson +0.20%
- NVAXNovavax +3.37%
- LLYEli Lilly & Co. -0.51%
- AZNAstraZeneca -1.49%
- ABBVABBVIE -0.53%
- BMYBristol-Myers Squibb Co. +0.64%
Who counts as related is the data provider's judgement, not a screen run here — there's no ranking implied, and no suggestion these are comparable investments. Changes are for the latest completed session.
Data as of 8/4/26, 5:07 PM (cached up to 30 seconds) · updates automatically while this page is open, during market hours
Company
PharmaceuticalsPfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Technical signals
Based on daily closesTechnical indicators describe past price behaviour. They are not investment advice.
Short interest Short interest The number of shares that have been sold short — borrowed and sold by investors betting the price will fall — usually quoted as a share of all shares outstanding. Exchanges collect it twice a month at settlement, so the figure lags by a couple of weeks. Below about 2% is unremarkable; above 20% puts a company among the most heavily shorted on the market. It describes how much money is positioned against the company, not what the share price will do: shorts are sometimes right, and a crowded short sometimes unwinds violently upward.
Shares sold short · reported twice monthlyShort interest is reported to the exchanges at settlement, twice a month, so the headline figure lags by a couple of weeks. The daily share of volume sold short is current but noisier — much of it is market-maker hedging that never becomes a lasting position. Neither figure predicts direction.